Health Level: How to Treat Dyslipidemia

Close metadata

Efficacy and safety of alirocumab in real clinical practice.

Authors:

Korneva V.A.

Petrozavodsk State University, Petrozavodsk, Russia

SPIN RSCI: 5079-0547
Scopus AuthorID: 8272899600

Skopets I.S.

Petrozavodsk State University, Petrozavodsk, Russia

SPIN RSCI: 4981-2363
Scopus AuthorID: 57190413290

Kuznetsova T.Yu.

Petrozavodsk State University, Petrozavodsk, Russia

SPIN RSCI: 8652-4559
Scopus AuthorID: 57220650493

Vezikova N.N.

Petrozavodsk State University, Petrozavodsk, Russia

SPIN RSCI: 3910-7360
Scopus AuthorID: 6505871479

List of references:

Кухарчук В. В., Ежов М. В., Сергиенко И. В., Арабидзе Г. Г., Бубнова М. Г., Балахонова Т. В., Гуревич В. С., Качковский М. А., Коновалов Г. А., Константинов В. О., Малышев П. П., Покровский С. Д., Соколов А. А., Сумароков А. Б., Горнякова Н. Б., Обрезан А. Г., Шапошник И. И., Анциферов М. Б., Аншелес А. А., Аронов Д. М., Ахмеджанов Н. М., Барбараш О. Л., Бойцов С. А., Воевода М. И., Галстян Г. Р., Галявич А. С., Драпкина О. М., Дупляков Д. В., Ерегин С. Я., Карпов Р. С., Карпов Ю. А., Козиолова Н. А., Космачев Е. Д., Небиеридзе Д. В., Недогода С. В., Олейников В. Э., Рагино Ю. И., Скибицкий В. В., Смоленская О. Г., Филиппов А. Е., Халимов Ю. Ш., Чазова И. Е., Шестакова М. В., Якушин С. С. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VII пересмотр. Атеросклероз и дислипидемии. 2020;38(1):7-40.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. htps://doi.org/10.1093/eurheartj/ehz455
https://doi.org/10.34687/2219-8202.JAD.2020.01.00014
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. https://doi.org/10.1056/NEJMoa1615664
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. https://doi.org/10.1056/NEJMoa1801174
Stock JK. DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe. Atherosclerosis. 2020;314:74-76. https://doi.org/10.1016/j.atherosclerosis.2020.09.023
https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=001d648b-2755-4dd3-9a85-1097927d0077
Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol. 2016 Nov 15;223:750-757. https://doi.org/10.1016/j.ijcard.2016.08.273
Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Jan-Feb;11(1):195-203.e4. https://doi.org/10.1016/j.jacl.2016.12.004
Goldberg AC, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Wooten M, Iydroose M, Dacus K, Minchew H, Dutton JA, Moriarty PM. A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients. J Clin Lipidol. 2020 Nov–Dec;14(6):818-824. https://doi.org/10.1016/j.jacl.2020.08.005
Schwartz GG, Szarek MM, Bhatt DL, et al. Alirocumab reduces risk of death after acute coronary syndrome in patients with persistently elevated atherogenic lipoproteins on intensive statin treatment. Presentation at American Heart Association Scientific Session (November 11, 2018), Chicago (Illinois), USA. [cited by Nov 10, 2018]. https://abstractsonline.com/pp8/#!/4682/presentation/59973
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020 Nov 7;41(42):4114-4123. https://doi.org/10.1093/eurheartj/ehaa498
Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-839. https://doi.org/10.1016/S2213-8587(16)30156-5
Sagris D, Ntaios G, Georgiopoulos G, Pateras K, Milionis H. Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. Eur J Intern Med. 2021 Mar;85:130-132. https://doi.org/10.1016/j.ejim.2020.11.021
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Ž, Roe MT, Szarek M, Tse HF, White HD, Zahger D, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021 Mar 23;28(1):33-43. https://doi.org/10.1177/2047487320941987
Benhuri B, Ueyama H, Takagi H, Briasoulis A, Kuno T. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials. Curr Vasc Pharmacol. 2021;19(4):390-397. https://doi.org/10.2174/1570161118666200807114559
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. https://doi.org/10.1016/j.jacc.2019.10.057
https://doi.org/10.20996/1819-6446-2018-14-6-922-934
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Investigators. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 Nov 21;41(44):4245-4255. https://doi.org/10.1093/eurheartj/ehaa649

Close metadata